Overview

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Crizotinib
Docetaxel
Pemetrexed